Editas Medicine
Adam Bartley has a solid work experience in the biopharmaceutical industry. Adam is currently working at Editas Medicine as the Vice President of Technical Operations, a role they have held since June 2022. Prior to that, they were the Senior Director of Cell Therapy Manufacturing, Lab Operations, and Facilities at Editas Medicine from November 2020 to June 2022.
Before joining Editas Medicine, Adam worked at Genzyme as the Head of Cell Culture Manufacturing and Global Cell Banking from November 2012 to November 2020. Adam also has experience at Shire HGT, where they held various leadership roles from January 2008 to November 2012. Earlier in their career, they worked at Wyeth BioPharma, where they held various positions from January 2002 to January 2008.
Adam Bartley earned a Bachelor of Science (B.S.) degree in Major Biology and Minor Chemistry from Notre Dame College between 1997 and 2001.
This person is not in any offices
Editas Medicine
5 followers
Editas Medicine is a leading genome editing company focused on translating the power and promise of our proprietary genome editing systems into medicines to help transform the lives of people with genetically-defined diseases. Their goal is to discover, develop, manufacture, and commercialize transformative medicines for a range of serious diseases, including eye diseases, blood diseases, and cancer.